NCT02323659 is a Phase 4 clinical trial of Methotrexate in Lymphoma, T-Cell, Cutaneous, sponsored by Polish Lymphoma Research Group.

Who is sponsoring NCT02323659?

NCT02323659 is sponsored by Polish Lymphoma Research Group.

What drugs are being tested in NCT02323659?

Interventions in NCT02323659: Methotrexate, Interferon Alfa-2b.

What condition does NCT02323659 study?

NCT02323659 studies Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides.

Is NCT02323659 still recruiting?

NCT02323659 is currently terminated. Last updated 23 December 2021.

Last reviewed 2021-12-23 · How we verify

NCT02323659

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas

Terminated Phase 4 Last updated 23 December 2021

What this trial tests

Phase 4 trial testing Methotrexate in Lymphoma, T-Cell, Cutaneous in 100 participants. Terminated before completion.

Timeline

1 June 2014

Primary endpoint
1 March 2018

31 March 2018

Quick facts

Lead sponsor	Polish Lymphoma Research Group
Phase	Phase 4
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 June 2014
Primary completion	1 March 2018
Estimated completion	31 March 2018
Sites	1 location across Poland

Drugs / interventions tested

Methotrexate — full drug profile →
Interferon Alfa-2b (INTERFERON ALFA-2B) — full drug profile →

Conditions studied

Lymphoma, T-Cell, Cutaneous — all drugs for Lymphoma, T-Cell, Cutaneous →
Mycosis Fungoides — all drugs for Mycosis Fungoides →

Sponsor

Polish Lymphoma Research Group

Who can join

18 and older, any sex, with Lymphoma, T-Cell, Cutaneous or Mycosis Fungoides. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Objective response rate as measured by the modified Severity Weighted Assessment Tool (mSWAT scoring system)
Time frame: 3 years
Evaluation according to modified Severity Weighted Assessment Tool (mSWAT scoring system)

Sponsor's own description

Comparison of methotrexate versus interferon-alfa 2b on efficacy, safety and quality of life in patients with primary cutaneous T-cell lymphomas after failure of topical or phototherapy treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Interventions for mycosis fungoides.
Valipour A, Jäger M, Wu P, Schmitt J, et al · · 2020 · cited 17× · PMID 32632956 · DOI 10.1002/14651858.cd008946.pub3
Efficacy, quality of life, and safety of methotrexate versus interferon in head-to-head treatment in advanced stages of mycosis fungoides and Sezary syndrome. Prospective trial (NCT02323659).
Chmielowska E, Sokołowska-Wojdyło M, Olszewska B, Studziński M, et al · · 2021 · cited 1× · PMID 36751548 · DOI 10.5114/ada.2021.106206

Verify or expand the search:

Other trials of Methotrexate

Trials testing the same drug.

NCT07498465 — A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant · Phase 1 · withdrawn
NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
NCT07321912 — Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma · Phase 2 · not yet recruiting
NCT07446400 — A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuva · Phase 1 · recruiting
NCT07477691 — Immune Modulation During Palynziq® Treatment in Adults (IMPALA) · Phase 4 · not yet recruiting

Other recruiting trials for Lymphoma, T-Cell, Cutaneous

Currently open trials in the same condition.

NCT03902184 — IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma · Phase 2 · active not recruiting

Other Polish Lymphoma Research Group trials

Trials by the same sponsor.

NCT04716075 — Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) · Phase 2 · completed
NCT03229382 — Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse · Phase 2 · terminated
NCT03615664 — The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABVD · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02323659 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Polish Lymphoma Research Group
Last refreshed: 23 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02323659.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing